Innoviva, Inc. (INVA)
Innoviva, Inc. (INVA) from its SEC filings: 2025 revenue $411.3 million (+15% vs the year before), free cash flow $195.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $411.3 million |
| Revenue growth | +15% |
| Free cash flow | $195.8 million |
| Diluted EPS | $3.30 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +19% |
| Cash | $570.4 million |
| Long-term debt | $258.5 million |
| Share count, 1 year | +15% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.